Exploring the Active Compounds of Traditional Mongolian Medicine Baolier Capsule (BLEC) in Patients with Coronary Artery Disease (CAD) Based on Network Pharmacology Analysis, Molecular Docking and Experimental Validation

被引:1
|
作者
Wei, Mengqiu [1 ]
Li, Fengjin [2 ]
Guo, Kai [3 ,4 ]
Yang, Tianxiao [5 ]
机构
[1] Zhongshan City Peoples Hosp, Intens Care Unit, Zhongshan 528400, Peoples R China
[2] Fujian Med Univ, Longyan Affiliated Hosp 1, Dept Gynecol, Longyan 36400, Peoples R China
[3] Guangdong Second Prov Gen Hosp, Dept Cardiol, Guangzhou 510000, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Emergency, Guangzhou 510000, Peoples R China
[5] Shandong Univ, Zibo Cent Hosp, Dept Cardiol, Zibo 255000, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
coronary artery disease; Baolier capsule; traditional Mongolian medicine; network pharmacology; experimental validation; TANSHINONE IIA; ATTENUATES ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; DOWN-REGULATION; BETA-CAROTENE; NARINGENIN; INFLAMMATION; CHOLESTEROL; MICE;
D O I
10.2147/DDDT.S395207
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: Baolier Capsule (BLEC) is a Traditional Mongolian Medicine comprising fifteen herbs. This study aims to illustrate the synergistic mechanism of BLEC in the treatment of Coronary Artery Disease (CAD) by using network pharmacology method, molecular docking and experimental validation. Methods: Searching and screening the active ingredients of different herbs in BLEC and target genes related to CAD in multiple databases. Subsequently, Protein-Protein Interactions Network (PPI-Net), gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment were used to identify the key targets. AutoDock was used to verify the binding ability between the active ingredient and key target through molecular docking. Reverse Transcription-Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) was used to verify the effect of active ingredient of BLEC on the key target gene. Finally, effect of BLEC on the degree of blood lipids and atherosclerosis was validated by animal experiment. Results: There are 144 active components and 80 CAD-related targets that are identified in BLEC in the treatment of CAD. What is more, 8 core genes were obtained by clustering and topological analysis of PPI-Net. Further, GO and KEGG analysis showed that fluid shear stress and atherosclerosis are the key pathways for BLEC to treat CAD. These results were validated by molecular docking method. In vitro, active compounds of BLEC (Quercetin, luteolin, kaempferol, naringenin, tanshinone IIA, beta-carotene, 7-O-methylisomucronulatol, piperine, isorhamnetin and Xyloidone) can inhibit 8 core gene (AKT1, EGFR, FOS, MAPK1, MAPK14, STAT3, TP53 and VEGFA) expression. Moreover, BLEC not only improve blood lipid levels but also inhibit the development of atherosclerosis in ApoE-knockout mice. Conclusion: Our research first revealed the basic pharmacological effects and related mechanisms of in the treatment of CAD. The predicted results provide some theoretical support for BLEC or its important active ingredients to treat CAD.
引用
收藏
页码:459 / 476
页数:18
相关论文
共 43 条
  • [21] Prediction of the active compounds and mechanism of Biochanin A in the treatment of Legg-Calvé-Perthes disease based on network pharmacology and molecular docking
    Liu, Jianhong
    Hua, Zhirui
    Liao, Shijie
    Li, Boxiang
    Tang, Shengping
    Huang, Qian
    Wei, Zhendi
    Lu, Rongbin
    Lin, Chengsen
    Ding, Xiaofei
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2024, 24 (01)
  • [22] Network pharmacology analysis and experimental verification of the antithrombotic active compounds of trichosanthis pericarpium (Gualoupi) in treating coronary heart disease
    Xia, Kai-rou
    Zhang, Xiao-yu
    Zhang, Huang-qin
    Su, Ke-lei
    Shang, Er-xin
    Xiao, Qing-ling
    Li, Wei-wen
    Guo, Sheng
    Duan, Jin-ao
    Liu, Pei
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 329
  • [23] Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of Tongxinluo capsule administered in coronary heart diseases
    Li, Guode
    Xu, Qingbo
    Han, Kedong
    Yan, Wenhe
    Huang, Chaopei
    BIOSCIENCE REPORTS, 2020, 40
  • [24] Exploring the Underlying Mechanism of Weiling Decoction Alleviates Cold-Dampness Diarrhea Based on Network Pharmacology, Transcriptomics, Molecular Docking and Experimental Validation
    Zhang, Yannan
    Zhang, Shuai
    Fan, Yimeng
    Huang, Sijuan
    Wang, Shimin
    Hao, Zhihui
    Shen, Jianzhong
    PHARMACEUTICALS, 2025, 18 (01)
  • [25] Exploring the anti-gastric cancer mechanism of action of Bidentis Bipinnatae Herba based on network pharmacology, molecular docking, and cellular experimental validation
    Guo, Linglong
    Zhou, Yuyi
    Ma, Rui
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (11) : 8681 - 8690
  • [26] Role of corn silk for the treatment of Alzheimer's disease: A mechanism research based on network pharmacology combined with molecular docking and experimental validation
    Tao, Tian-ze
    Wang, Lu
    Liu, Jie
    CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 102 (05) : 1231 - 1247
  • [27] Network pharmacology analysis and molecular docking using the Chinese herbal agent WYHX formula (according to Yan Dexin): Management of coronary artery disease
    Wang, Zi-Yang
    Zhou, Miao
    Sun, Yong-Ning
    Hu, Xiao-Zhen
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (08) : 363 - 376
  • [28] Exploring the Active Ingredients and Mechanism of Action of Huanglian Huazhuo Capsule for the Treatment of Obese Type-2 Diabetes Mellitus Based on Using Network Pharmacology and Molecular Docking
    Wang, Na
    An, Wen-bo
    Zhou, Nan
    Fan, Jing-chun
    Feng, Xin
    Yang, Wei-jie
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [29] Investigating the active compounds and mechanism of HuaShi XuanFei formula for prevention and treatment of COVID-19 based on network pharmacology and molecular docking analysis
    Wang, Juan
    Ge, Wen
    Peng, Xin
    Yuan, Lixia
    He, Shuaibing
    Fu, Xuyan
    MOLECULAR DIVERSITY, 2022, 26 (02) : 1175 - 1190
  • [30] Investigating the active compounds and mechanism of HuaShi XuanFei formula for prevention and treatment of COVID-19 based on network pharmacology and molecular docking analysis
    Juan Wang
    Wen Ge
    Xin Peng
    Lixia Yuan
    Shuaibing He
    Xuyan Fu
    Molecular Diversity, 2022, 26 : 1175 - 1190